8-K: Nexalin Technology Closes $5.25 Million Public Offering

Nexalin Technology successfully closed a public offering of 3,000,000 shares, raising approximately $5.25 million in gross proceeds.

Summary

• Nexalin Technology, Inc. completed a public offering of 3,000,000 shares of its common stock.
• The offering was priced at $1.75 per share.
• The gross proceeds from the offering totaled approximately $5,250,000.
• Maxim Group LLC acted as the sole placement agent for the offering.
• The company intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
• The offering was made under a registration statement on Form S-1, which was declared effective on June 27, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully raised capital, but there are standard risks and costs associated with the offering.

Positives

• The successful completion of the public offering provides Nexalin with additional capital.
• The funds raised can be used to support the company's operations and growth initiatives.
• The offering was completed with the assistance of a reputable placement agent, Maxim Group LLC.

Negatives

• The company incurred placement agent fees equal to 8% of the gross proceeds.
• The company also reimbursed the placement agent $110,000 for expenses related to the offering.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The company's forward-looking statements are subject to numerous conditions beyond their control.
• The company's actual results could differ materially from those indicated in forward-looking statements.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, including working capital, operating expenses, and capital expenditures. The company's future performance is subject to risks and uncertainties.

Management Comments

• Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders.
• Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects.

Industry Context

The announcement highlights Nexalin's efforts to secure funding for its neurostimulation technology, which is aimed at addressing the global mental health epidemic. This is part of a broader trend of investment in innovative medical technologies targeting mental health.

Comparison to Industry Standards

• The capital raise of $5.25 million is relatively small compared to larger pharmaceutical or medical device companies, but is typical for a company of Nexalin's size and stage.
• The use of a placement agent like Maxim Group LLC is a standard practice for public offerings of this nature.
• The 8% placement fee is within the typical range for such transactions.

Stakeholder Impact

• Shareholders will see an increase in the number of outstanding shares.
• The company's employees may benefit from the increased financial stability.
• Customers may benefit from the company's ability to further develop its products.

Next Steps

• The company will use the net proceeds for general corporate purposes.
• The company will continue to develop and market its neurostimulation products.

Key Dates

Keywords

Public Offering, Capital Raise, Common Stock, Placement Agent, Neurostimulation, Mental Health, Nexalin Technology, Maxim Group LLC